The combination of podoplanin expression levels and IDH1 mutation status predicts VTE risk in patients with brain tumors. Issue 164 (April 2018) - Nazari, P.M.S.; Riedl, J.; Preusser, M.; Posch, F.; Thaler, J.; Marosi, C.; Birner, P.; Ricken, G.; Hainfellner, J.A.; Pabinger, I.; Ay, C.